EmpleoRelaciones con InversoresComunicados de Prensa
  1. Siemens Healthineers México
  2. Diagnóstico de Laboratorio
  3. Assays by Diseases & Conditions
  4. Liver Fibrosis Assays 
  5. Real-World Evidence & Value of the ELF Test

Real-World Evidence & Value of the ELF Test

Assessing fibrosis risk with a more accessible blood test can help improve clinical and financial outcomes

Introduction of non-invasive tests in primary care has the potential to:

  • Increase the early detection of advanced fibrosis and cirrhosis in NAFLD patients.
  • Reduce unnecessary referrals to secondary care of patients at low risk of advanced liver disease.
  • Deliver immediate and sustained significant cost savings.

BBC StoryWorks: A MedTech Europe Documentary Style Short Film

Hear from a NAFLD patient and clinical experts about how the ELF Test has the ability to improve outcomes for patients and transform systems of care. 

person holding sample tube

ELF Featured in the News

Hear Dr. Kirsten Frederiksen, Renown physician, speak to the use of the ELF Test in relation to The Healthy Nevada Project created by the Renown Institute for Health Innovation.1,2
chairs in a waiting room

ELF Helps NHS Tayside Reduce Liver Clinic Waiting List by Almost Half 

Find out how NHS Tayside uses the ELF Test to help identify priority patients at risk.3

A Novel Two-step Pathway to Detect Liver Cirrhosis Earlier

Camden and Islington are two working class cities in the UK with an estimated NAFLD prevalence of 20%-30%. To reduce the burden of unnecessary referrals and improve detection of advanced liver disease, a “NAFLD pathway” was developed comprised of testing first with FIB-4 and reflexing indeterminate results to ELF. After 2 years the pathway data was compared to the Standard of Care.4,5

    Hear From the Expert:
    The Two Step Pathway Using Non-invasive Tests

    In this video, Dr. Ankur Srivastava, Consultant Gastroenterologist and Hepatologist at Southmead Hospital, North Bristol Trust, discusses his two-step primary care pathway approach of utilizing non-invasive tests to reduce unnecessary referrals and improve detection of severe disease in patients with NAFLD. This work was recently published in the Journal of Hepatology.

    ELF Test identified as an important component of NAFLD clinical practice guidelines by the Chronic Liver Disease Foundation (CLDF)6

    A small expert panel of hepatologists was tasked with creating straight-forward guidelines subsequent to the 2019 CLDF leadership forum. ELF plays a central role in the staging algorithm, and is the only proprietary serum fibrosis marker recommended by the expert panel.

    The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

    References
    1

    https://healthynv.org/current-studies/liver-study/

    2

    https://www.globenewswire.com/news-release/2020/12/15/2145575/0/en/RENOWN-INSTITUTE-FOR-HEALTH-INNOVATION-EXPANDS-PARTNERSHIP-WITH-GILEAD-SCIENCES-AND-SIEMENS-HEALTHINEERS-TO-OFFER-ELF-ENHANCED-LIVER-FIBROSIS-TESTING-FOR-NEVADA-NASH-STUDY-PARTICIP.html

    3

    https://www.nhstayside.scot.nhs.uk/News/Article/index.htm?article=PROD_344800

    4

    Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6.

    5

    Srivastava, A. et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 19, 122 (2019) doi:10.1186/s12876-019-1039-4

    6

    Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Younossi ZM, et al. Am J Gastro. 2020;00:1–9. https://doi.org/10.14309/ajg.0000000000001054